JPS5924137B2 - 弱毒ウイルスの製造方法 - Google Patents
弱毒ウイルスの製造方法Info
- Publication number
- JPS5924137B2 JPS5924137B2 JP47121264A JP12126472A JPS5924137B2 JP S5924137 B2 JPS5924137 B2 JP S5924137B2 JP 47121264 A JP47121264 A JP 47121264A JP 12126472 A JP12126472 A JP 12126472A JP S5924137 B2 JPS5924137 B2 JP S5924137B2
- Authority
- JP
- Japan
- Prior art keywords
- virus
- interferon
- attenuated
- pharmaceutical
- inducer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 241000700605 Viruses Species 0.000 title claims description 58
- 230000002238 attenuated effect Effects 0.000 title claims description 22
- 238000004519 manufacturing process Methods 0.000 title claims description 10
- 239000002799 interferon inducing agent Substances 0.000 claims description 43
- 102000014150 Interferons Human genes 0.000 claims description 21
- 108010050904 Interferons Proteins 0.000 claims description 21
- 229940079322 interferon Drugs 0.000 claims description 18
- 230000000890 antigenic effect Effects 0.000 claims description 8
- 230000007246 mechanism Effects 0.000 claims description 7
- 230000037125 natural defense Effects 0.000 claims description 7
- 230000006698 induction Effects 0.000 claims description 6
- 230000028993 immune response Effects 0.000 claims description 3
- 229940047124 interferons Drugs 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 33
- 239000003085 diluting agent Substances 0.000 description 24
- 238000000034 method Methods 0.000 description 23
- 241001465754 Metazoa Species 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 14
- 239000000203 mixture Substances 0.000 description 12
- 208000015181 infectious disease Diseases 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000007921 spray Substances 0.000 description 8
- 229960005486 vaccine Drugs 0.000 description 8
- 230000009385 viral infection Effects 0.000 description 8
- 230000002458 infectious effect Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 208000036142 Viral infection Diseases 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 239000000825 pharmaceutical preparation Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 5
- -1 for example Substances 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 241000282887 Suidae Species 0.000 description 4
- 230000008260 defense mechanism Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 206010022000 influenza Diseases 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 235000012216 bentonite Nutrition 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000008298 dragée Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 206010002199 Anaphylactic shock Diseases 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 240000002470 Amphicarpaea bracteata Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010048461 Genital infection Diseases 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108010093857 Viral Hemagglutinins Proteins 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000004665 defense response Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000005454 flavour additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000009027 insemination Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000019685 rice crackers Nutrition 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 208000037974 severe injury Diseases 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000011410 subtraction method Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 208000010484 vulvovaginitis Diseases 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16732—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16761—Methods of inactivation or attenuation
- C12N2710/16764—Methods of inactivation or attenuation by serial passage
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2161344 | 1971-12-10 | ||
| DE2161344A DE2161344C3 (de) | 1971-12-10 | 1971-12-10 | Herstellung von Virusstämmen, welche die natürlichen Abwehrmechanismen eines Wirtsorganismus stimulieren, ohne dabei gleichzeitig antigen zu wirken und Arzneimittel zur Prophylaxe und Behandlung von viralen und bakteriellen Infektionen des Menschen und der Tiere, einen solchen Virusstamm enthaltend |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS4862919A JPS4862919A (cs) | 1973-09-01 |
| JPS5924137B2 true JPS5924137B2 (ja) | 1984-06-07 |
Family
ID=5827622
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP47121264A Expired JPS5924137B2 (ja) | 1971-12-10 | 1972-12-05 | 弱毒ウイルスの製造方法 |
| JP47121265A Expired JPS6011013B2 (ja) | 1971-12-10 | 1972-12-05 | 動物用薬剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP47121265A Expired JPS6011013B2 (ja) | 1971-12-10 | 1972-12-05 | 動物用薬剤 |
Country Status (22)
| Country | Link |
|---|---|
| JP (2) | JPS5924137B2 (cs) |
| AR (1) | AR204075A1 (cs) |
| AT (1) | AT326817B (cs) |
| AU (1) | AU473209B2 (cs) |
| BE (1) | BE792484A (cs) |
| BG (1) | BG21417A3 (cs) |
| CA (1) | CA988848A (cs) |
| CH (1) | CH577558A5 (cs) |
| CS (1) | CS189587B2 (cs) |
| DD (1) | DD108115A5 (cs) |
| DE (1) | DE2161344C3 (cs) |
| DK (1) | DK143201C (cs) |
| ES (1) | ES409464A1 (cs) |
| FR (1) | FR2162637B1 (cs) |
| GB (1) | GB1356076A (cs) |
| HU (1) | HU167086B (cs) |
| IE (1) | IE36995B1 (cs) |
| NL (1) | NL178014C (cs) |
| PH (1) | PH12597A (cs) |
| SE (1) | SE8400283D0 (cs) |
| SU (1) | SU439956A3 (cs) |
| ZA (1) | ZA728709B (cs) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0063657A1 (en) * | 1981-04-29 | 1982-11-03 | Merck & Co. Inc. | Topical application of interferon inducers |
-
0
- BE BE792484D patent/BE792484A/xx not_active IP Right Cessation
-
1971
- 1971-12-10 DE DE2161344A patent/DE2161344C3/de not_active Expired
-
1972
- 1972-01-01 AR AR245553A patent/AR204075A1/es active
- 1972-12-01 PH PH14135A patent/PH12597A/en unknown
- 1972-12-02 SU SU1853618A patent/SU439956A3/ru active
- 1972-12-05 JP JP47121264A patent/JPS5924137B2/ja not_active Expired
- 1972-12-05 JP JP47121265A patent/JPS6011013B2/ja not_active Expired
- 1972-12-06 BG BG022052A patent/BG21417A3/xx unknown
- 1972-12-07 AT AT1041972A patent/AT326817B/de not_active IP Right Cessation
- 1972-12-07 NL NLAANVRAGE7216628,A patent/NL178014C/xx not_active IP Right Cessation
- 1972-12-07 CS CS728391A patent/CS189587B2/cs unknown
- 1972-12-08 HU HUBA2833A patent/HU167086B/hu unknown
- 1972-12-08 DK DK615472A patent/DK143201C/da not_active IP Right Cessation
- 1972-12-08 DD DD167455A patent/DD108115A5/xx unknown
- 1972-12-08 ZA ZA728709A patent/ZA728709B/xx unknown
- 1972-12-08 CH CH1791372A patent/CH577558A5/xx not_active IP Right Cessation
- 1972-12-08 GB GB5672372A patent/GB1356076A/en not_active Expired
- 1972-12-08 IE IE1716/72A patent/IE36995B1/xx unknown
- 1972-12-08 CA CA158,535A patent/CA988848A/en not_active Expired
- 1972-12-08 FR FR7243868A patent/FR2162637B1/fr not_active Expired
- 1972-12-09 ES ES409464A patent/ES409464A1/es not_active Expired
- 1972-12-11 AU AU49920/72A patent/AU473209B2/en not_active Expired
-
1984
- 1984-01-20 SE SE8400283A patent/SE8400283D0/xx not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BE792484A (fr) | 1973-06-08 |
| ATA1041972A (de) | 1975-03-15 |
| CA988848A (en) | 1976-05-11 |
| DE2161344C3 (de) | 1986-10-02 |
| NL178014B (nl) | 1985-08-01 |
| DE2161344A1 (de) | 1973-06-20 |
| SE8400283L (sv) | 1984-01-20 |
| JPS4862912A (cs) | 1973-09-01 |
| CH577558A5 (cs) | 1976-07-15 |
| AU4992072A (en) | 1974-06-13 |
| DE2161344B2 (de) | 1980-05-08 |
| AU473209B2 (en) | 1976-06-17 |
| ZA728709B (en) | 1973-08-29 |
| PH12597A (en) | 1979-06-27 |
| JPS4862919A (cs) | 1973-09-01 |
| DK143201C (da) | 1981-12-14 |
| AR204075A1 (es) | 1975-11-20 |
| NL178014C (nl) | 1986-01-02 |
| HU167086B (cs) | 1975-08-28 |
| SU439956A3 (ru) | 1974-08-15 |
| IE36995B1 (en) | 1977-04-13 |
| IE36995L (en) | 1973-06-10 |
| NL7216628A (cs) | 1973-06-13 |
| FR2162637A1 (cs) | 1973-07-20 |
| AT326817B (de) | 1975-12-29 |
| JPS6011013B2 (ja) | 1985-03-22 |
| SE8400283D0 (sv) | 1984-01-20 |
| DD108115A5 (cs) | 1974-09-05 |
| DK143201B (da) | 1981-07-20 |
| FR2162637B1 (cs) | 1976-07-02 |
| ES409464A1 (es) | 1976-03-16 |
| GB1356076A (en) | 1974-06-12 |
| CS189587B2 (en) | 1979-04-30 |
| BG21417A3 (bg) | 1976-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3530526B2 (ja) | ＨＳＶ糖蛋白質ｇＤおよび３脱アシル化モノホスホリルリピッドＡからなる単純ヘルペスワクチン | |
| JPH01279842A (ja) | Ａ型及びｂ型肝炎混合アジュバントワクチン | |
| Prince et al. | Immunoprotective Activity and Safety of a RespiratorySyncytial Virus Vaccine: Mucosal Delivery of Fusion Glycoprotein with aCpG OligodeoxynucleotideAdjuvant | |
| Huang | Vaccination against and immune response to viral haemorrhagic disease of rabbits: a review of research in the People’s Republic of China | |
| Iosef et al. | Systemic and intestinal antibody secreting cell responses and protection in gnotobiotic pigs immunized orally with attenuated Wa human rotavirus and Wa 2/6-rotavirus-like-particles associated with immunostimulating complexes | |
| CA1095407A (en) | Preparation for the treatment of herpes zoster and other herpes infections, as well as method for manufacture thereof | |
| US4049794A (en) | Treatment of infections in animals | |
| Levy et al. | Topical treatment of vaccinia virus infection with an interferon inducer in rabbits | |
| US4039656A (en) | Production of attenuated viruses | |
| CN108969492B (zh) | 一种猪瘟口服弱毒冻干疫苗及其制备方法 | |
| Glasgow et al. | Isoprinosine: lack of antiviral activity in experimental model infections | |
| Shipkowitz et al. | Antiviral activity of a bis-benzimidazole against experimental rhinovirus infections in chimpanzees | |
| WO1986000529A1 (en) | An antiviral preparation and the method of its production | |
| US4017359A (en) | Production of non-antigenic attenuated viruses | |
| JPS5924137B2 (ja) | 弱毒ウイルスの製造方法 | |
| AU2009100451A4 (en) | Medicinal formulation containing a combination of HIV Type I and HIV Type II | |
| DE2616406B2 (de) | Mittel zur Prophylaxe und Therapie der Gastro-Enteritis | |
| CN116115746A (zh) | 含有木鳖子总皂苷和铝盐的疫苗佐剂及其疫苗组合物 | |
| CN108703952B (zh) | 一种猪瘟口服弱毒冻干疫苗用冻干保护剂及应用 | |
| RU2180238C1 (ru) | Биологический препарат для профилактики и лечения желудочно-кишечных и респираторных болезней телят | |
| Clark Jr et al. | Effect of Actinospectacin (Trobicin) in Experimental Syphilis in the Rabbit—II: II. IN SUBCLINICAL INCUBATING SYPHILIS | |
| Cunliffe et al. | Interferon inducers and foot-and-mouth disease vaccines: influence of two synthetic polynucleotides on antibody response and immunity in guinea pigs and swine | |
| Rogers et al. | Sensitization of guinea pigs to herpes simplex virus | |
| Adu et al. | Serum-virus simultaneous method of immunisation against peste des petits ruminants | |
| Stringfellow et al. | Feline interferon response to 2-amino-5-bromo-6-methyl-4-pyrimidinol (U-25,166) |